EichorEICHOR
Condition: Neuroendocrine Neoplasm Of Gastrointestinal Tract Disorder Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Neuroendocrine Neoplasm Of Gastrointestinal Tract Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391Spanish Series of Patients Treated With the Radionuclide Lutetium177
Phase N/A · 20 location(s) · Sociedad Española de Medicina Nuclear e Imagen Molecular · NCT04949282Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Beijing Tide Pharmaceutical Co., Ltd · NCT07371663A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116EQUITY GI: A Prospective Study to Enhance Quality, Inclusivity, and Trial Participation in Black Patients With Gastroint
NA · 1 location(s) · Case Comprehensive Cancer Center · NCT06263088START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer
Phase 1 · 7 location(s) · Valo Therapeutics Oy · NCT05492682A Study of IBI363 in Subjects with Advanced Solid Malignancies
Phase 2 · 9 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06281678The Florida ASCENT Study
NA · 1 location(s) · University of Florida · NCT07042243A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic So
Phase 1/Phase 2 · 120 location(s) · Daiichi Sankyo · NCT06330064Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
NA · 13 location(s) · European Organisation for Research and Treatment of Cancer - · NCT04498767Risk Factors for Neuroendocrine Neoplasms
Phase N/A · 1 location(s) · Bavarian Cancer Registry · NCT06282016Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/Phase 2 · 21 location(s) · Children's Oncology Group · NCT04851119Urinary Microbiome as a Biomarker for Melanoma Diagnosis and Response Prediction to Systemic Tumour Therapy
Phase N/A · 1 location(s) · Medical University of Graz · NCT07635732A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 · 12 location(s) · Pliant Therapeutics, Inc. · NCT06270706Pan-tumor MRD Study
Phase N/A · 2 location(s) · Paradigm Health · NCT06605404A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Phase 1/Phase 2 · 5 location(s) · 7 Hills Pharma, LLC · NCT06362369A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
Phase 1 · 3 location(s) · Conjupro Biotherapeutics, Inc. · NCT07317505Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985Liquid Biopsy Evaluation and Repository Development at Princess Margaret
Phase N/A · 1 location(s) · University Health Network, Toronto · NCT03702309Explorative Study on Addition of High-fiber Dried Chicory Root in Patients With an Intermediate to High-risk Cutaneous M
NA · 1 location(s) · University Medical Center Groningen · NCT07206017DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With H
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770102MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 · 3 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT0751719818F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis
Phase N/A · 1 location(s) · Nanjing First Hospital, Nanjing Medical University · NCT06937112Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid
Phase 1 · 3 location(s) · Anusha Kalbasi · NCT04119024
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.